To date, investigations into IL-26 as a biomarker have been conducted in breast cancer [82], colorectal cancer [33], pancreatic ductal adenocarcinoma [128], and HCC [123]. This evidence concerns the gene IL26 and pancreatic ductal adenocarcinoma.